MedPath

Apalutamide

Generic Name
Apalutamide
Brand Names
Erleada
Drug Type
Small Molecule
Chemical Formula
C21H15F4N5O2S
CAS Number
956104-40-8
Unique Ingredient Identifier
4T36H88UA7
Background

Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of Bicalutamide or Enzalutamide. Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines .

Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies.

Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer .

Indication

Apalutamide is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.

Associated Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
Associated Therapies
Androgen Deprivation Therapy
Clinical Trials
Related News

STEERLife Unveils Solvent-Free Melt Fusion Technology for Potent Drug Development

• STEERLife has introduced a groundbreaking solvent-free melt fusion technology that eliminates harmful organic solvents in pharmaceutical manufacturing, enhancing safety and efficiency. • The company has initiated development of generic versions of several high-potency drugs including Apalutamide, Enzalutamide, Venetoclax, and Olaparib, with market releases planned from 2026. • Through strategic partnerships, STEERLife aims to serve pharmaceutical markets across multiple regions including the United States, Europe, Latin America, and Asia.

Veracyte Expands Decipher Prostate Test to Metastatic Cancer Patients, Offering New Treatment Guidance Tool

• Veracyte has launched the Decipher Prostate Metastatic Genomic Classifier, making it the only gene expression test covered by Medicare across all prostate cancer risk levels. • The 22-gene test helps identify which metastatic prostate cancer patients will likely benefit from available treatments, potentially sparing others from unnecessary toxic side effects. • Clinical validity has been demonstrated in multiple prospective Phase 3 studies, building on the test's established utility in localized prostate cancer where it achieved "Level I" evidence status in NCCN Guidelines.

CD46-Targeting ADC FG-3246 Shows Promising Results in Advanced Prostate Cancer Trial

• FG-3246, a first-in-class antibody-drug conjugate targeting CD46, demonstrated an 80% disease control rate and 20% objective response rate in heavily pre-treated metastatic castration-resistant prostate cancer patients. • The phase 1 trial established 2.7 mg/kg as the maximum tolerated dose, with manageable safety profile including neutropenia as the most common adverse event, while showing a median radiographic progression-free survival of 8.7 months. • FibroGen plans to advance FG-3246 with a phase 2 monotherapy study by mid-2025 and will disclose results from a combination trial with enzalutamide in the second half of 2025.

Pathos AI Initiates Phase 1b/2a Trial of Pocenbrodib for Metastatic Castration-Resistant Prostate Cancer

• Pathos AI has dosed the first patient in a Phase 1b/2a trial evaluating pocenbrodib, a CBP/p300 inhibitor, alone and in combination with established therapies for metastatic castration-resistant prostate cancer. • The multicenter trial will enroll approximately 203 patients who have progressed despite prior therapy, with primary objectives to assess safety, response rates, and determine recommended Phase 2 dosing. • Pocenbrodib targets underlying resistance mechanisms to AR-targeted therapy through CBP/p300 inhibition, addressing a significant unmet need in advanced prostate cancer treatment.

Phase 3 PROSTATE-IQ Trial Launches to Reduce Hormone Therapy Burden in Prostate Cancer Patients

• The phase 3 PROSTATE-IQ trial has enrolled its first patient, evaluating ArteraAI Prostate Test's ability to identify men who can safely reduce or avoid hormone therapy after prostatectomy. • The study will stratify patients with biochemical recurrence into risk groups, with low-risk patients receiving either 6 months of ADT or apalutamide monotherapy, while high-risk patients receive either 24 months of ADT or 6 months of ADT with apalutamide. • Led by Dr. Karen Elizabeth Hoffman from MD Anderson Cancer Center, the trial aims to improve quality of life by minimizing hormone therapy side effects while maintaining treatment efficacy across 11 clinical sites in the US.

TuHURA Biosciences Appoints Former J&J Oncology Executive Craig Tendler to Board of Directors

• TuHURA Biosciences has appointed Craig L. Tendler, M.D., former Vice President of Oncology Clinical Development at Johnson & Johnson, to its Board of Directors effective March 10, 2025. • Dr. Tendler brings extensive experience overseeing 30 major drug approvals and 13 FDA Breakthrough Designations, including transformational treatments for hematologic malignancies, prostate, lung, and bladder cancers. • The appointment comes as TuHURA prepares to advance its lead candidate IFx-2.0, designed to overcome resistance to checkpoint inhibitors, into a Phase 3 registrational trial in Q2 2025.

Zydus Launches ANVIMO: Game-Changing CMV Prevention Drug for Transplant Patients at 91% Lower Cost

• Zydus Lifesciences introduces ANVIMO (letermovir) in India, offering a breakthrough treatment for preventing Cytomegalovirus infection in stem cell and kidney transplant patients. • The new drug demonstrates superior safety profile and reduced side effects compared to traditional treatments, while maintaining bioequivalence with the reference drug. • ANVIMO's launch dramatically reduces treatment costs by 91% compared to imported alternatives, making critical CMV prophylaxis more accessible to Indian transplant patients.

Nanoform Reports Strong Growth and Advances in Nanoparticle Drug Development Pipeline

• Nanoform achieved record project signings in 2024 with revenue growth of 87% in Q4, marking a strong recovery after six quarters of decline. • The company is advancing three key product developments - Nanoenzalutamide, Nanoapalutamide, and Nanoencorafenib - with deal discussions intensifying and expected closures in coming months. • Nanoenzalutamide's pivotal bioequivalence studies are set to begin in Q2 2025, targeting a 2027/28 market launch as a patient-friendly alternative to Xtandi® with reduced pill burden.

Darolutamide Demonstrates Superior Benefits in Black and White Patients with Non-Metastatic Prostate Cancer

• Real-world evidence from the DEAR study reveals darolutamide offers longer treatment duration and delayed progression compared to enzalutamide and apalutamide in non-metastatic castration-resistant prostate cancer patients. • Among 1,205 patients studied, darolutamide showed lower discontinuation rates (32.8% Black, 37.9% White) compared to enzalutamide (44.8% Black, 53.1% White) and apalutamide (48.8% Black, 50.4% White). • Median metastasis-free survival was not reached in the darolutamide group for both racial cohorts, while enzalutamide and apalutamide groups showed shorter survival periods.

TALAPRO-2 Trial: Talazoparib-Enzalutamide Combo Shows Significant Survival Benefit in Metastatic Prostate Cancer

• The combination of talazoparib and enzalutamide demonstrated an 8.8-month improvement in overall survival compared to enzalutamide alone in metastatic castration-resistant prostate cancer patients. • Patients with homologous recombination repair-deficient tumors showed an even more pronounced benefit, with a 14-month survival improvement and 38% reduction in death risk. • The phase 3 TALAPRO-2 trial revealed manageable safety profiles with no new concerns, despite grade 3/4 anemia occurring in 49% of patients, which was effectively managed through dose adjustments.

Quality of Life Comparable Between Erleada Combinations in Advanced Prostate Cancer Treatment

• New study published in JAMA Network Open reveals no significant differences in health-related quality of life between Erleada alone or combined with Zytiga and Deltasone in advanced prostate cancer patients. • Treatment efficacy data showed promising PSA response rates across all groups, with two-year survival rates exceeding 87% and highest at 92.7% for the Erleada plus Zytiga/Deltasone combination. • While overall side effect profiles were similar between treatment groups, Erleada monotherapy showed lower rates of hot flashes and hypertension but higher incidence of gynecomastia and breast pain.

J&J Boosts Neuroscience Pipeline with ITCI Acquisition, FDA Approves Spravato Monotherapy for TRD

• Johnson & Johnson (J&J) is set to acquire Intra-Cellular Therapies (ITCI) for $14.6 billion, adding Caplyta for bipolar disorder and schizophrenia to its neuroscience pipeline. • The FDA has approved J&J's Spravato as a monotherapy for treatment-resistant depression (TRD), based on positive data from the phase IV TRD4005 study. • AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) received FDA priority review for a lung cancer indication and was approved for previously treated breast cancer.

ORIC Pharmaceuticals Announces Promising Early Data for ORIC-944 and Collaboration for ORIC-114

• ORIC Pharmaceuticals reported encouraging early data from a Phase 1b trial of ORIC-944 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC). • The company entered a clinical trial collaboration with Johnson & Johnson to evaluate ORIC-114 with amivantamab for first-line treatment of NSCLC with EGFR exon 20 insertion mutations. • ORIC anticipates seven data readouts across ORIC-114 and ORIC-944 programs in the next 18 months, potentially leading to registrational trials in 2025 and 2026.

EMA Begins Review of Xtandi for Hormone-Sensitive Prostate Cancer

The European Medicines Agency (EMA) has initiated a review of Pfizer and Astellas' prostate cancer drug, Xtandi, for a new indication that could expand its use to metastatic hormone-sensitive prostate cancer (mHSPC) patients, based on the phase 3 ARCHES and ENZAMET trials. This move could intensify competition with Johnson & Johnson's Zytiga, which was approved for mHSPC last year in the US.

FDA Grants Priority Review to CUTX-101 for Menkes Disease, Offering Hope for Rare Pediatric Condition

• The FDA has accepted Sentynl Therapeutics' NDA for CUTX-101, granting priority review for the treatment of Menkes disease, a rare genetic disorder. • Clinical trials of CUTX-101 demonstrated an almost 80% reduction in mortality risk compared to untreated patients, significantly improving overall survival. • CUTX-101 has been granted multiple designations, including Breakthrough Therapy and Orphan Drug, highlighting its potential to address a critical unmet need. • Cyprium Therapeutics is eligible to receive up to $129 million in milestone payments and royalties, retaining ownership of a potential Priority Review Voucher.

Advances in Prostate Cancer: From Novel Therapies to Enhanced Diagnostics

• Relugolix plus radiotherapy demonstrates safety and efficacy for localized and advanced prostate cancer, offering a potential new treatment approach. • The FDA cleared an IND application for 225Ac-J591, a PSMA-targeted monoclonal antibody, for advanced prostate cancer, marking progress in targeted therapy. • Apalutamide shows improved overall survival compared to enzalutamide in metastatic castration-sensitive prostate cancer, according to a retrospective analysis. • The Decipher Prostate Genomic Classifier received a Level 1B evidence rating in NCCN guidelines, enhancing its role in risk stratification and treatment decisions.

Advances in Metastatic Prostate Cancer: Novel Treatment Strategies Emerge

• The ARANOTE trial demonstrated that darolutamide plus ADT significantly improves radiographic progression-free survival in mHSPC patients. • PEACE-3 trial results highlighted that combining radium-223 with enzalutamide significantly improved outcomes in mCRPC patients with bone metastases. • SPLASH trial data suggests 177Lu-PNT2002 may offer a new radioligand therapy option for mCRPC patients who have progressed after an ARPI.

FDA Approves Obecabtagene Autoleucel for R/R B-ALL; Advances in SCLC and Multiple Myeloma Highlighted

• The FDA approved obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) based on the phase 1b/2 FELIX trial data. • Tarlatamab and lurbinectedin are shifting the treatment landscape for small cell lung cancer (SCLC) due to their improved toxicity profiles. • LBL-034, a bispecific antibody targeting GPRC5D and CD3, received orphan drug designation for multiple myeloma treatment and is being evaluated in a phase 1/2 trial.

Apalutamide Demonstrates Superior Overall Survival Compared to Enzalutamide in mCSPC

• A real-world study of nearly 4,000 patients with metastatic castration-sensitive prostate cancer (mCSPC) showed apalutamide (ERLEADA®) reduced the risk of death by 23% compared to enzalutamide at 24 months. • The study applied FDA real-world evidence guidance, using robust methodology and diverse data sources to ensure the validity of its findings in comparing the two androgen receptor pathway inhibitors. • 87.6% of patients initiating apalutamide were alive at 24 months, consistent with the Phase 3 TITAN trial results, reinforcing apalutamide's survival benefit in mCSPC. • These real-world insights can inform prescribers when choosing an ARPI for mCSPC, highlighting apalutamide as a patient-centric, once-daily treatment option.

Lutetium Lu 177 Vipivotide Tetraxetan Shows Promise in Prostate Cancer Treatment

• Lutetium Lu 177 vipivotide tetraxetan has emerged as a significant radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). • Studies indicate potential for earlier use of Lutetium Lu 177 vipivotide tetraxetan, before chemotherapy, offering improved tolerability and quality of life for patients. • Research explores combining Lutetium Lu 177 vipivotide tetraxetan with other therapies, such as androgen receptor pathway inhibitors, to enhance treatment synergy. • Ongoing trials are investigating novel targets and treatment strategies to address resistance and improve outcomes in advanced prostate cancer.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy